Effect of Intravenous Infusion of G-CSF-Mobilized Peripheral Blood Mononuclear Cells on Upper Extremity Function in Cerebral Palsy Children
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective To investigate the effect of intravenous infusion of peripheral blood mononuclear cells (mPBMC) mobilized by granulocyte-colony stimulating factor (G-CSF) on upper extremity function in children with cerebral palsy (CP).Methods Fifty-seven children with CP were enrolled. Ten patients were excluded due to follow-up loss. In total, 47 patients (30 males and 17 females) were analyzed. All patients’ parents provided signed consent before the start of the study. After administration of G-CSF for 5 days, mPBMC was collected and cryopreserved. Patients were randomized into two groups 1 month later. Twenty-two patients were administered mPBMC and 25 patients received normal saline as placebo. Six months later, the two groups were switched, and administered mPBMC and placebo, respectively. Quality of Upper Extremity Skills Test (QUEST) and the Manual Ability Classification System (MACS) were used to evaluate upper motor function.Results All subdomain and total scores of QUEST were significantly improved after mPBMC and placebo infusion, without significant differences between mPBMC and placebo groups. A month after G-CSF, all subdomain and total scores of QUEST were improved. The level of MACS remained unchanged in both mPBMC and placebo groups. Conclusion In this study, intravenously infused mPBMC showed no significant effect on upper extremity function in children with CP, as compared to placebo. The effect of mPBMC was likely masked by the effect of G-CSF, which was used in both groups and/or G-CSF itself might have other neurotrophic potentials in children with CP.
Abstract
Objective To investigate the effect of intravenous infusion of peripheral blood mononuclear cells (mPBMC) mobilized by granulocyte-colony stimulating factor (G-CSF) on upper extremity function in children with cerebral palsy (CP).Methods Fifty-seven children with CP were enrolled. Ten patients were excluded due to follow-up loss. In total, 47 patients (30 males and 17 females) were analyzed. All patients’ parents provided signed consent before the start of the study. After administration of G-CSF for 5 days, mPBMC was collected and cryopreserved. Patients were randomized into two groups 1 month later. Twenty-two patients were administered mPBMC and 25 patients received normal saline as placebo. Six months later, the two groups were switched, and administered mPBMC and placebo, respectively. Quality of Upper Extremity Skills Test (QUEST) and the Manual Ability Classification System (MACS) were used to evaluate upper motor function.Results All subdomain and total scores of QUEST were significantly improved after mPBMC and placebo infusion, without significant differences between mPBMC and placebo groups. A month after G-CSF, all subdomain and total scores of QUEST were improved. The level of MACS remained unchanged in both mPBMC and placebo groups. Conclusion In this study, intravenously infused mPBMC showed no significant effect on upper extremity function in children with CP, as compared to placebo. The effect of mPBMC was likely masked by the effect of G-CSF, which was used in both groups and/or G-CSF itself might have other neurotrophic potentials in children with CP.
참고문헌 (26)
- Colver A, "Cerebral palsy", Lancet, 383, pp.1240~1249 (2014)
- Koman LA, "Cerebral palsy", Lancet, 363, pp.1619~1631 (2004)
- McIntyre S, "A systematic review of risk factors for cerebral palsy in children born at term in developed countries", Dev Med Child Neurol, 55, pp.499~508 (2013)
- Mancias-Guerra C, "Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an openlabel phase I trial", Cytotherapy, 16, pp.810~820 (2014)
- Wang X, "Effects of bone marrow mesenchymal stromal cells on gross motor function measure scores of children with cerebral palsy: a preliminary clinical study", Cytotherapy, 15, pp.1549~1562 (2013)
- Purandare C, "Therapeutic potential of autologous stem cell transplantation for cerebral palsy", Case Rep Transplant, 2012, pp.825289~ (2012)
- Deng J, "Bone marrow mesenchymal stem cells can be mobilized into peripheral blood by G-CSF in vivo and integrate into traumatically injured cerebral tissue", Neurol Sci, 32, pp.641~651 (2011)
- Huss R, "Evidence of peripheral blood-derived, plastic-adherent CD34(-", low) hematopoietic stem cell clones with mesenchymal stem cell characteristics, 2000, pp.18, 252~260
- Law M, "Neurodevelopmental therapy and upper-extremity inhibitive casting for children with cerebral palsy", Dev Med Child Neurol, 33, pp.379~387 (1991)
- Thorley M, "Reliability of the quality of upper extremity skills test for children with cerebral palsy aged 2 to 12 years", Phys Occup Ther Pediatr, 32, pp.4~21 (2012)
- Jeevanantham D, "The manual ability classification system: a scoping review", Pediatr Phys Ther, 27, pp.236~241 (2015)
- Alvarez P, "Regulatory systems in bone marrow for hematopoietic stem", progenitor cells mobilization and homing, 2013, pp.2013, 312656~
- Kopen GC, "Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains", Proc Natl Acad Sci U S A, 96, pp.10711~10716 (1999)
- Faulkner SD, "The potential for stem cells in cerebral palsy: piecing together the puzzle", Semin Pediatr Neurol, 20, pp.146~153 (2013)
- Brenneman M, "Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats", J Cereb Blood Flow Metab, 30, pp.140~149 (2010)
- Carroll JE, "Update on stem cell therapy for cerebral palsy", Expert Opin Biol Ther, 11, pp.463~471 (2011)
- Mathieu M, "Cell therapy with autologous bone marrow mononuclear stem cells is associated with superior cardiac recovery compared with use of nonmodified mesenchymal stem cells in a canine model of chronic myocardial infarction", J Thorac Cardiovasc Surg, 138, pp.646~653 (2009)
- Sharma A, "A clinical study of autologous bone marrow mononuclear cells for cerebral palsy patients: a new frontier", Stem Cells Int, 2015, pp.905874~ (2015)
- Iwase T, "Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia", Cardiovasc Res, 66, pp.543~551 (2005)
- Ukai R, "Mesenchymal stem cells derived from peripheral blood protects against ischemia", J Neurotrauma, 24, pp.508~520 (2007)
- Schneider A, "A role for G-CSF (granulocyte-colony stimulating factor) in the central nervous system", Cell Cycle, 4, pp.1753~1757 (2005)
- Moon JH, "Safety and efficacy of G-CSF mobilization and collection of autologous peripheral blood stem cells in children with cerebral palsy", Transfus Apher Sci, 49, pp.516~521 (2013)
- Koh H, "Mononuclear cells from the cord blood and granulocytecolony stimulating factor-mobilized peripheral blood: is there a potential for treatment of cerebral palsy?", Neural Regen Res, 10, pp.2018~2024 (2015)
- England TJ, "Granulocyte-colony stimulating factor for mobilizing bone marrow stem cells in subacute stroke: the stem cell trial of recovery enhancement after stroke 2randomized controlled trial", Stroke, 43, pp.405~411 (2012)
- Grassinger J, "Safety and feasibility of long term administration of recombinant human granulocyte-colony stimulating factor in patients with amyotrophic lateral sclerosis", Cytokine, 67, pp.21~28 (2014)
- Schabitz WR, "Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia", Stroke, 34, pp.745~751 (2003)